药源性急性肾损伤研究进展

摘要/Abstract

摘要： 药物作为疾病预防、治疗和诊断的重要手段，也是造成急性肾损伤（AKI）的因素之一。肾毒性药物种类繁多，可以是单一药物亦可是多种药物联合应用而致病。药源性AKI发病机制多样，以急性肾小管坏死和间质性肾炎为主。发病的高危因素涉及药物因素（如：药物自身的肾脏毒性、使用剂量与疗程）和患者因素（如：高龄、血容量不足、慢性肾脏病基础）。本文就临床常见及易忽视的肾毒性药物进行综述，旨在提高对肾毒性药物及发生药源性AKI风险因素的认知，为临床用药提供参考与警示。

关键词: 急性肾损伤, 肾毒性药物, 发病机制, 高危因素

Abstract: As an important part of disease prevention, treatment and diagnosis, drugs are the common source of acute kidney injury (AKI). There are various kinds of nephrotoxic drugs, and AKI can be induced either by a single drug or combination of several drugs. The main mechanisms of drug-induced AKI include acute tubular necrosis and acute interstitial nephritis. The risk factors involve drug-related factors (such as nephrotoxicity, dosage and duration) and patient-related factors (such as age, hypovolemia, chronic kidney disease). This article is a review of common or unnoticeable nephrotoxic drugs on the purpose of calling for attention to nephrotoxic drugs and AKI risk factors and providing warnings for clinical drug use.

Key words: acute kidney injury, nephrotoxic drugs, pathogenesis, risk factors

中图分类号:

R994.11

范倩倩,孔旭东,邓昂,唐昆. 药源性急性肾损伤研究进展[J]. 中国药物警戒, 2015, 12(3): 164-168.

FAN Qian-qian,KONG Xu-dong,DENG Ang,TANG Kun. Study Progress of Drug-induced Acute Kidney Injury[J]. Chinese Journal of Pharmacovigilance, 2015, 12(3): 164-168.

参考文献

[1] Kidney Disease Improving Global Outcomes. Definition and classification of AKI[J]. Kidney Int, 2012,2（s1）:19-36.
[2] Ali T，Khan I，Simpson W, et a1. Incidence and outcomes in acute kidney injury: a comprehensive population-based study[J]. J Am Soc Nephrol, 2007,18(4):1292-1298.
[3] Lewington A J, Cerda J, Mehta R L. Raising awareness of acute kidney injury：a global perspective of a silent killer[J]. Kidney Int, 2013,84(3):457-467.
[4] Luyckx V A, Naicker S. Acute kidney injury associated with the use of traditional medicines[J]. Nat Clin Pract Nephrol, 2008,4(12):664-671.
[5] Pannu N, Nadim M K. An overview of drug-induced acute kidney injury[J]. Cri Care Med, 2008,36(4Suppl):S216-223.
[6] 王俊锋. 2007-2014年我国药物性急性肾损伤文献调查与分析[J]. 临床误诊误治, 2014,27(10):54-57.
[7] 张彤, 梅长林. 急性肾衰竭100例临床分析[J]. 中华肾脏病杂志, 2005,21(12):732-735.
[8] 陈伟, 刘华锋. 抗菌药物相关急性肾损伤的新认识[J]. 临床合理用药, 2010,3(1):124-126.
[9] 张媛媛, 刘华锋. 非甾体类抗炎药相关急性肾衰竭新进展[J]. 医学综述, 2010,16(22):3450-3452.
[10] 李中东, 王大猷. COX-2抑制剂与急性肾衰[J]. 药物不良反应杂志, 2001,3(1):56.
[11] 郭晨雯, 范春, 王京鹰. 环氧化酶II 选择性抑制剂的临床应用及存在的问题[J]. 中国医院药学杂志, 2003,23(9):559-560.
[12] Musu M, Finco G, Antonucci R, et al. Acute nephrotoxicity of NSAID from the foetus to the adult[J]. Eur Rev Med Pharmacol Sci, 2011,15(12):1461-1472.
[13] Bentley M L, Corwin H L, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies[J]. Cri Care Med, 2010,38 (s6):S169-S174.
[14] Nash K, Hafeez A, Hou S. Hospital-aquired renal insufficiency[J]. Am J Kidney Dis, 2002, 39(5):930-936.
[15] 韩雅玲. 重视对比剂诱导的急性肾损伤[J]. 解放军医学杂志, 2014,39(4):255-258.
[16] Rudnick M R, Goldfarb S, Tumlin J. Contrast-induced nephropathy: is the picture any clearer[J]. Clin J Am Soc Nephrol, 2008,3(1):261-262.
[17] Schetz M, Dasta J, Goldstein S, et al. Drug-induced acute kidney injury[J]. Curr Opin Crit Care, 2005,11(6):555-565.
[18] Ruffenach S J, Siskind M S, Lien Y H. Acute interstitial nephritis due to omeprazole[J]. Am J Med, 1992,93(4):472-473.
[19] Torpey N, Barker T, Ross C. Drug-induced tubule-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit[J].Nephrol Dial Transplant, 2004,19(6):1441-1446.
[20] Geevasinga N, Coleman P L, Roger S D. Rabeprazole-induced acute interstitial nephritis[J]. Nephrology (Carlton), 2005,10(1):7-9.
[21] Simpson I J, Marshall M R, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases[J]. Nephrology(Carlton), 2006,11(5):381-385.
[22] Klepser D G, Collier D S, Cochran G L. Proton pump inhibitors and acute kidney injury: a nested case-control study[J]. BMC Nephrol, 2013,14:150.
[23] Muriithi A K, Leung N, Valeri A M, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series[J]. Am J Kidney Dis, 2014,64(4):558-566.
[24] 程骏章, 姜鸿. 奥美拉唑致过敏性紫癜性肾炎1例[J]. 中国药师, 2007,10(5):477.
[25] 张晓东, 方敬爱, 武明虎. 奥美拉唑导致间质性肾炎的临床分析[J]. 中国中西医结合肾病杂志, 2006,7(9):543.
[26] Muriithi A K, Leung N, Valeri A M, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly[J/OL]. Kidney Int, 2015,87 (2):458-464.
[27] Brewster U C, Perazella M A. Proton pump inhibitors and the kidney: critical review[J]. Clin Nephrol, 2007,68(2):65-72.
[28] Perazella M A, Markowitz G S. Drug-induced acute interstitial nephritis[J]. Nat Rev Nephrol, 2010,6(8):461-470.
[29] Brewster U C, Perazella M A. Acute kidney injury following proton pump inhibitor therapy[J]. Kidney Int, 2007,71(6):589-593.
[30] Geevasinga N, Coleman P L, Webster A C, et al. Proton pump inhibitors and acute interstitial nephritis[J]. Clin Gastroenterol Hepatol, 2006,4(5):597-604.
[31] Blank M L, Parkin L, Paul C， et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use[J]. Kidney Int, 2014,86(4):837-844.
[32] Fisher A A, Le Couteur D G. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists [J]. Drug Saf, 2001,24(1):39-57.
[33] Gaughan W J, Sheth V R, Francos G C, et al. Ranitidine-induced acute interstitial nephritis with epithelial cell foot process fusion[J]. Am J Kidney Dis, 1993,22 (2):337-340.
[34] Neelakantappa K, Gallo G R, Lowenstein J. Ranitidine-associated interstitial nephritis and Fanconi syndrome[J]. Am J Kidney Dis, 1993,22(2):333-336.
[35] Russo A, Mirani A, Perlman J, et al. Enalapril-induced acute kidney injury in neonates[J]. J Neonatal Perinatal Med, 2013,6(2):179-181.
[36] Hanevold C D. Acute renal failure during lisinopril and losartan therapy for proteinuria[J]. Pharmacotherapy, 2006,26(9):1348-1351.
[37] Phillips C O, Kashani A, Ko D K, et a1. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction[J]. Arch Intern Med, 2007,167(18):1930-1936.
[38] Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin- (1-7)-Mas receptor axis[J]. Hypertens Res, 2009,32(7):533-536.
[39] 谷松磊, 白海涛. 血管紧张素转换酶抑制剂和血管紧张素II 1型受体拮抗剂抑制血管紧张素II促增殖在急性肾损伤发生发展中的作用[J]. 临床内科杂志, 2013,30(6):431-432.
[40] Scherpbier N D, de Grauw W J, Wetzels J F, et al. Acute renal failure due to RAAS-inhibitors combined with dehydration[J]. Ned Tijdschr Geneeskd, 2010,154:A1548.
[41] Townsend R R, Cohen D L. Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury[J]. Evid Based Med, 2013,18(6):232-233.
[42] 何兰, 周巧玲. Netrin-1在急性肾损伤中的作用[J]. 中国医师杂志, 2011,2(z2):200-202.
[43] Cruz C S, Cruz L S, Silva G R, et al. Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors[J]. Nephron Clin Pract, 2007,105(2):77-83.
[44] Ejaz A A, Fitzpatrick P M, Haley W E, et al. Amlodipine besylate induced acute interstitial nephritis[J]. Nephron, 2000,85(4):354-356.
[45] Naha K, Suryanarayana J, Aziz R A, et al. Amlodipine poisoning revisited: acidosis, acute kidney injury and acute respiratory distress syndrome[J]. Indian J Crit Care Med, 2014,18(7):467-469.
[46] Kute V B, Shah P R, Goplani K R, et al. Successful treatment of refractory hypotension, noncardiogenic pulmonary edema and acute kidney injury after an overdose of amlodipine[J]. Indian J Crit Care Med, 2011,15(3):182-184.
[47] Gandhi S, Fleet J L, Bailey D G, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury[J]. JAMA. 2013,310(23):2544-2553.
[48] Markowitz G S, Perazella M A. Acute phosphate nephropathy[J]. Kidney Int, 2009,76(10):1027-1034.
[49] Ori Y, Rozen-Zvi B, Chagnac A, et al. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience [J]. Arch Intern Med, 2012,172(3):263-265.
[50] FDA. Oral Sodium Phosphate (OSP) Products for Bowel Cleansing[EB/OL].(2006-03)[2014-11-25].http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders%20/ucm161565.htm.
[51] FDA. Oral Sodium Phosphate (OSP) Products for Bowel Cleansing (marketed as Visicol and OsmoPrep, and oral sodium phosphate products available without aprescription)[EB/OL].(2008-11-12)[2014-11-25]. http://www.fda.gov/Drugs/DrugSafety/Post marketDrugSafetyInformationforPatientsandProviders/ucm126084.htm.
[52] FDA. FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation[EB/OL].(2014-08-01)[2014-11-25].http://www.fda.gov/Drugs/DrugSafety/ucm380757.htm.
[53] Markowitz G S, Nasr S H, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing[J]. Hum Pathol, 2004,35 (6):675-684.
[54] Gumurdulu Y, Serin E, Ozer B, et al. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation[J]. J Gastroenterol Hepatol, 2004,19(1):68-72.
[55] Brunelli S M, Lewis J D, Gupta M, et al. Risk of kidney injury following oral phosphosoda bowel preparations[J]. J Am Soc Nephrol, 2007,18(2):3199-3205.
[56] Barclay R L. Safety, efficacy, and patient tolerance of a three-dose regimen of orally administered aqueous sodium phosphate for colonic cleansing before colonoscopy[J]. Gastrointest Endosc, 2004, 60(4):527-533.
[57] Russmann S, Lamerato L, Motsko S P, et al. Risk of further decline in renal function after the use of oral sodium phosphate or polyethy-lene glycol in patients with a preexisting glomerular filtration rate below 60 ml/min[J]. Am J Gastroenterol, 2008,103(11):2707-2716.
[58] Khurana A, McLean L, Atkinson S, et al. The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy[J]. Arch Intern Med, 2008,168(6):593-597.
[59] Eremina V, Jefferson J A, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy[J]. N Engl J Med, 2008,358(11):1129-1136.
[60] Muallem S, Moe O W. When EGF is offside, magnesium is wasted[J]. J Clin Invest, 2007,117 (8):2086-2089.
[61] Perazella M A, Markowitz G S. Bisphosphonate nephrotoxicity[J]. Kidney Int, 2008,74(11):1385-1393.
[62] 张玉萌, 栗晓东, 刘萍,等. 穿心莲制剂引起急性肾毒性的文献回顾性分析[J]. 中国药物应用与监测, 2010,7(6):360-362.
[63] 易扬, 马骏, 王汉清,等. 白蔹致急性肾损伤一例[J]. 中华肾脏病杂志, 2014,30(3):235-236.
[64] 解倩, 陆敏, 申洪波,等. 中汤药相关性急性肾损伤患者32例临床分析[J]. 中国老年学杂志, 2011,31(24):4804-4805.
[65] 段永红. 致肾损害中药品种文献分析[J]. 海峡药学, 2014,26 (4):138-139.
[66] 堪贻璞. 中草药引起的肾损害[J]. 中华肾脏病杂志, 2005,21(3):121-122.
[67] 尹世强, 邹爱英, 刘秀书,等. 中药导致肾损害相关性分析及预防[J]. 天津药学, 2013,25(4):55-57.